Non Hodgkin Lymphoma Clinical Trial
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
Summary
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Relapsed or refractory CD19+ expressing malignancies
At least 2 prior regimens per Standard of Care
Exclusion Criteria:
No history of active CNS involvement
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 7 Locations for this study
See Locations Near You
Banner MDA
Gilbert Arizona, 85234, United States More Info
Gilbert Arizona, 85234, United States More Info
Rajneesh Nath, MD
Contact
Contact
Rajneesh Nath, MD
Principal Investigator
Principal Investigator
City of Hope
Duarte California, 91010, United States More Info
Duarte California, 91010, United States More Info
Alex Herrera, MD
Contact
Contact
Alex Herrera, MD
Principal Investigator
Principal Investigator
Moffitt Cancer Center
Tampa Florida, 33612, United States More Info
Tampa Florida, 33612, United States More Info
Michael Jain, MD
Contact
Contact
Michael Jain, MD
Principal Investigator
Principal Investigator
Tufts Medical Center
Boston Massachusetts, 02111, United States More Info
Boston Massachusetts, 02111, United States More Info
Andreas Klein, MD
Contact
Contact
Andreas Klein, MD
Principal Investigator
Principal Investigator
Columbia University
New York New York, 10032, United States More Info
New York New York, 10032, United States More Info
Ran Reshef, MD
Contact
Contact
Ran Reshef, MD
Principal Investigator
Principal Investigator
Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States More Info
Philadelphia Pennsylvania, 19107, United States More Info
Usama Gergis, MD
Contact
Contact
Usama Gergis, MD
Principal Investigator
Principal Investigator
Lifespan Cancer Institute at Rhode Island Hospital
Providence Rhode Island, 02903, United States More Info
Providence Rhode Island, 02903, United States More Info
Adam Olszewski, MD
Contact
Contact
Adam Olszewski, MD
Principal Investigator
Principal Investigator
How clear is this clinincal trial information?